This three-wave syndicated research series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for relapsed/refractory multiple myeloma. This series is based on primary research data collected at one month, three months, and one year postcommercial availability of Darzalex and Empliciti. Along with awareness and sources of familiarity, our analysis assesses U.S. hematological oncologists’ trial, adoption, and use of these agents, including anticipated future trends. Our content provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Johnson & Johnson/Janssen’s and Bristol-Myers Squibb’s promotional efforts, and benchmarking against other agents for multiple myeloma.

Table of contents

  • Multiple Myeloma - Emerging Therapies - Darzalex/Empliciti Launch Tracking Wave 2 (US)
    • Key Findings
      • Benchmarking Darzalex and Empliciti Launch Success Versus the Competition
        • Darzalex and Empliciti Compare Well Against Benchmarks
        • Benchmarking Darzalex and Empliciti Launch Success vs. the Competition
      • Prescriber and Nonprescriber Profiles
        • Differences Between Darzalex and Empliciti Prescribers and Nonprescribers
        • Darzalex Prescriber vs. Nonprescriber Profile
        • Empliciti Prescriber vs. Nonprescriber Profile
      • Darzalex and Empliciti Awareness and Perceptions
        • Unaided and Aided Awareness of Darzalex and Empliciti
          • Unaided Recall of Select Drugs for Multiple Myeloma
          • Prompted Awareness of Darzalex and Empliciti
        • Familiarity with Darzalex and Empliciti
          • Darzalex and Empliciti Familiarity Ratings
          • Mean Familiarity Levels: Prescribers vs. Nonprescribers
          • Darzalex: Approved Patient Populations
          • Empliciti: Approved Patient Populations
          • Estimated Monthly Costs of Darzalex and Empliciti Therapy
          • Estimated Mean Monthly Costs of Darzalex and Empliciti Therapy
        • Sources of Familiarity with Darzalex and Empliciti
          • Information Sources Promoting Familiarity with Darzalex and Empliciti
          • Physician Quotes on Sources of Familiarity with Darzalex and Impliciti
        • Initial Reactions to and Interest in Darzalex and Empliciti
          • Initial Reactions to Darzalex and Empliciti
          • Levels of Interest in Darzalex and Empliciti
          • Physician Quotes on Initial Reaction to and Interest in Darzalex and Empliciti
        • Impressions of Darzalex and Empliciti
          • Views on the Uniqueness of Darzalex and Empliciti
          • Perceived Advantages of Darzalex and Empliciti
          • Perceived Disadvantages of Darzalex and Empliciti
          • Physician Quotes on Impressions of Darzalex
          • Physician Quotes on Impressions of Empliciti
      • Darzalex and Empliciti Trial and Use
        • Willingness to Prescribe Darzalex and Empliciti
          • Enthusiasm Is High for Darzalex and Empliciti
          • Willingness to Prescribe Darzalex and Empliciti
          • Anticipated Future Product Use by Nonprescribers
        • Number of Patients Now Receiving Darzalex and Empliciti
          • Two-Thirds of Respondents Are Now Darzalex and/or Empliciti Prescribers
          • Uptake of Darzalex and Empliciti by Hematological Oncologists
          • Mean Numbers of Patients Now Receiving Darzalex and Empliciti
          • Median Numbers of Patients Now Receiving Darzalex and Empliciti
          • Percentage of Patients Receiving Darzalex and Discontinuations
          • Percentage of Patients Receiving Empliciti and Discontinuations
          • Reasons for Discontinuation of Darzalex
          • Reasons for Discontinuation of Empliciti
          • Percentage of Patients In Whom Dosages Were Withheld Due to AEs
          • Extent of Admitted Off-Label Prescribing of Darzalex and Empliciti
          • Extent of Prescribing of Darzalex and Empliciti by Line of Therapy
          • Treatment of Multiple Myeloma by Line of Therapy
          • Impact of the Launch of Darzalex and Empliciti on Treatment Regimens
          • Physician Quotes on Current Use of Darzalex
          • Physician Quotes on Current Use of Empliciti
        • Reasons for Not Yet Prescribing Darzalex and Empliciti
          • Caution and Cost-Effectiveness Concerns Prevail
          • Physician Quotes on Reasons for Not Prescribing Darzalex and Empliciti
        • Anticipated Darzalex and Empliciti Use
          • Insurance Plan Treatment Duration Restrictions Relaxed
          • Therapies Likely to Be Replaced by Darzalex and/or Empliciti
          • Darzalex Treatment Durations: Insurance Plan Restriction Trends
          • Empliciti Treatment Durations: Insurance Plan Restriction Trends
          • Managed Care Approval Requirements for Darzalex and Empliciti
          • Managed Care Approval Process Ratings for Darzalex and Empliciti
          • Percentage of Darzalex and Empliciti Prescriptions Denied by MCOs
          • Main Reasons for Darzalex Prescription Denial
          • Main Reasons for Empliciti Prescription Denial
          • Physician Quotes on Anticipated Darzalex Use
          • Physician Quotes on Anticipated Empliciti Use
        • Darzalex and Empliciti Performance on Key Attributes
          • Satisfaction Levels Remain High
          • Risk:Benefit Ratings for Darzalex and Empliciti in Multiple Myeloma
          • Overall Levels of Satisfaction for Darzalex and Empliciti in Multiple Myeloma
          • Levels of Satisfaction with the Efficacy of Darzalex and Empliciti in Multiple Myeloma
          • Levels of Satisfaction with the Safety and Tolerability of Darzalex and Empliciti in Multiple Myeloma
          • Determinants of Treatment Selection
          • Darzalex and Empliciti: Attribute Performance Ratings
          • Darzalex and Empliciti: Comparative Attribute Selections
      • Effectiveness of Face-to-Face Detailing for Darzalex and Empliciti
        • Darzalex and Empliciti Sales Representative Frequency and Reach
          • Call Frequency Rates Are Maintained for Darzalex but Falter for Empliciti
          • Sales Representative Call Frequency Rates
        • Satisfaction with Darzalex and Empliciti Sales Representatives
          • Darzalex and Empliciti Sales Representatives Are Highly Regarded by Prescribers
          • Sales Performance Rating on Select Major Attributes
        • Darzalex and Empliciti Message Recall
          • Topics Discussed by Sales Representatives
          • Distribution of Patient Education Materials
          • Physician Quotes on Darzalex Message Recall
          • Physician Quotes on Empliciti Message Recall
      • Methodology
        • Primary Market Research Methodology
      • Appendix
        • List of Abbreviatons
          • Additional Information
            • Clinical Practice Experience
            • Clinical Practice Set-up
            • Number of Multiple Myeloma Patients Managed Per Month
            • Number of Hematological Oncologists Per Physician Practice
            • Clinical Practice Location
            • US State of Practice Location
            • Awareness About Currently Available Drug Treatments for Multiple Myeloma
            • Level of Familiarity with the Following Drugs for Multiple Myeloma Treatment
            • Average Level of Familiarity with the Various Drugs for Multiple Myeloma Treatment
            • Gaps in Awareness About Darzalex and Empliciti Profiles Substatially Lower in Wave 2 As Compared to Wave 1
            • Patient Profile of Off-label Prescriptions of Darzalex
            • Patient Profile of Off-label Prescriptions of Empilicti
            • Key Reasons for Prescribing Another Agent Over Darzalex in the Fourth-line
            • Key Reasons for Prescribing Another Agent over Empliciti in the Relapsed/Refractory Settings
            • Factors Holding Back Physicians from Prescribing Darzalex in the Fourth-line
            • Factors Holding Back Physicians from Prescribing Empliciti in the Relapsed/Refractory Settings
            • Impact on Prescription of the Other Agents for Relapsed/Refractory Multiple Myeloma Since the Commercial Availability of Darzalex and Empliciti
            • About 15% Increase, in Comparison to Wave 1, in Coordinated Dosing Schedules, of Darzalex and/or Empliciti Prescribed Outside of Clinical Trials for Relapsed/Refractory Multiple Myeloma Patients, to Minimize Drug Wastage
            • Influence of Managed Care Approval Process Darzalex and/or Empliciti Prescriptions
            • Number of Relapsed/Refractory Multiple Myeloma Patients Inquiring About Darzalex and Empliciti in the Past Month
            • Percentage of Patients Actually Put on Therapy Among Those with Specific Inquiry About Darzalex and/or Empliciti
            • Most Likely Prescription in Various Multiple Myeloma Patient Settings
            • Preferred Therapy Choices for Patient with Multiple Myeloma Previously Prescribed Velcade + Dexamethasone (BD)
            • Miniscule rise in Preference for Darzalex Prescription, in Comparison to Wave 1, for Patient with Multiple Myeloma Previously Prescribed Velcade + Dexamethasone (BD)
            • Slight Drop in Empliciti Prescribers, in Comparison to Wave 1, for Patient with Multiple Myeloma Previously Prescribed Velcade + Dexamethasone (BD)
            • Change in Therapy Choice If Patient Received Revlimid + Dexamethasone (Rd) First Line and Disease Was Well Controlled for 24 Months
            • Preferred Therapy Choices for Patient with Multiple Myeloma Previously Prescribed Revlimid + dexamethasone (Rd) in First-Line
            • Preferred Therapy Choices for a Patient with Multiple Myeloma that Quickly Progressed to Fourth Line Therapy
            • Slight Drop in Darzalex Prescribers, in Comparison to Wave 1, for Patient with Multiple Myeloma that Quickly Progressed to Fourth Line Therapy
            • Slight Rise in Empliciti Prescribers, in Comparison to Wave 1, for Patient with Multiple Myeloma that Quickly Progressed to Fourth Line Therapy
            • Average Level of Performance of Sales Representative
            • Willingness for a Follow Up Interview About Darzalex and/or Empliciti

      Author(s): Izabela Ammermann, PhD; Dana Gheorghe

      Izabela Ammermann, Ph.D., M.Sc., is a business insights analyst in the oncology division at Decision Resources Group. She is a specialist in multiple myeloma and pancreatic cancer and has expertise in chronic lymphocytic leukemia. Dr. Ammermann holds a Ph.D. in molecular biology from the Technical University of Munich and a M.Sc. in biotechnology from the Polish Academy of Sciences. Prior to joining Decision Resources Group, Dr. Ammermann worked as a postdoctoral research associate (Marie Curie research fellow) at Imperial College London. Dr. Ammermann has published several peer-reviewed papers.

      Dana Gheorghe, Ph.D., is a senior business insights analyst on the Oncology team at Decision Resources Group, specializing in non-Hodgkin’s lymphoma and renal cell carcinoma, with expertise in multiple myeloma and metastatic colorectal cancer. Her previous experience includes postdoctoral positions at Imperial College London and the Marie Curie Research Institute. Dr. Gheorghe holds a Ph.D. in cellular biology and biochemistry from the University of Sheffield and a B.Sc./Honors in Molecular Biology from the University of Edinburgh.


      Related Reports

      Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast

      The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed...

      View Details

      Multiple Myeloma - Epidemiology - Emerging Markets

      DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries w...

      View Details

      Multiple Myeloma - Epidemiology - Mature Markets

      DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We re...

      View Details

      Multiple Myeloma - Epidemiology - Extrapolated Worldwide Coverage

      DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple myeloma patient pop...

      View Details